Back to News
Market Impact: 0.4
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Source: zacks.com
Healthcare & BiotechCompany Fundamentals
SNDX shares plunged 16% after its phase II axatilimab study missed the primary endpoint. The company abandoned development of the drug for idiopathic pulmonary fibrosis.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.60
Ticker Sentiment
SNDX-0.85
More News
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Netwealth stock sliding today?
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment
- Bending Spoons Stock Soars on Berkshire’s Increased Stake
- Ambani’s Jio seeks to raise $3.2B in what could be India’s biggest IPO